Genfit SA (GNFT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genfit SA is making strides in their liver disease programs, with Ipsen set to present new data on elafibranor at The Liver Meeting 2024 and positive commercial progress in the U.S. and Europe. The company is also advancing its Acute-on-Chronic Liver Failure (ACLF) program, with multiple clinical trials planned for 2025 and recent protocol improvements to enhance trial recruitment. These developments highlight Genfit’s commitment to expanding its presence in the liver health sector and improving patient outcomes.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.